Moving Forward. Giving Back.
Oncology & Haematology
Today, over 17 million new cancer cases are diagnosed globally each year, with the burden expected to rise by 70% over the next two decades. While remarkable breakthroughs have been achieved, such as targeted therapies and immunotherapies, challenges persist. Approximately 9.6 million lives are lost annually to cancer, underscoring the critical need for continued research, innovation, and access to effective treatments.
Today
In the present landscape, oncology and haematology pose significant challenges. Cancer continues to impact the lives of millions of individuals worldwide.
The complexity of these diseases, coupled with the need for more effective treatments, underscores the urgency to find innovative solutions. However, there is a shortage of specialised talent in these areas, hindering progress and limiting the pace of advancements.
Bridging this skillset gap is crucial to accelerating research, clinical trials, and therapeutic development.
Tomorrow
Looking ahead, the future of oncology holds immense promise.
Scientific breakthroughs, emerging technologies, and a deeper understanding of disease mechanisms are transforming the field. Targeted therapies, precision medicine, and personalised treatments are revolutionising patient care, offering new hope and improved outcomes.
This exciting future is characterised by groundbreaking approaches that have the potential to reshape the way we diagnose, treat, and manage cancers/
Tx Five
Tx Five works at the forefront of oncology, partnering with true market leaders who are embracing the future of healthcare.
In an industry facing a significant skills shortage, we proactively expand our network of experts to address the evolving demands. From personalised medicine and targeted therapies to immunotherapies and precision diagnostics, we are proud to have a network of industry leaders in the latest scientific approaches.
Our commitment to staying ahead of the curve allows us to empower our clients with access to the market leading experts shaping the future of oncology research.
Recent partnerships have resulted in successful trial initiations using various approaches including mAbs, ADCs, oncoloytic viruses, T-cell and traditional